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ABSTRACT
Background: Allogeneic hematopoietic stem cell transplantation (HSCT) is a curative treat-
ment option in both adult and pediatric patients with malignant and non-malignant hemato-
logical diseases. Chimerism analysis, which determines the donor or recipient origin of
hematopoietic cells in HSCT recipients, is an essential aspect of post-HSCT follow-up.
Objectives: To review the current literature and develop Belgian consensus guidelines for the
use of chimerism analysis in the standard of care after allogeneic HSCT.
Methods: Non-systematic review of the literature in consultancy with the members of the BHS
transplantation committee.
Results: Clinical applicationwith regards to predictionof graft failure or relapse aswell as cell source
are reviewed. A consensus guideline on the use of chimerism analysis after HSCT is presented.
Conclusion: Monitoring of the dynamics or kinetics of a patient’s chimerism status by serial analysis
at fixed time points, as well as on suspicion of relapse or graft failure, is needed to monitor







Allogeneic hematopoietic stem cell transplantation
(HSCT) is a curative treatment option in both adult and
pediatric patients with malignant and non-malignant
hematological diseases. The introduction of reduced
intensity conditioning (RIC) regimens as well as advances
in donor selection and supportive care have led to
a reduction in the treatment-related mortality associated
with allogeneic HSCT, allowing an increasing number of
patients to benefit from this treatment. In Belgium, 641
allogeneic HSCTs were performed between 1/1/2016 and
31/12/2017, of which 412 (64%) RIC HSCTs.
However, disease relapse and secondary graft failure
remain an important cause of treatment failure post allo-
geneic HSCT. Early detection of relapse andmonitoring of
engraftment levels are an essential aspect of post-HSCT
follow-up. The level of engraftment can be monitored
post-HSCT by determining the genotype of origin of
hematopoietic cells, or chimerism analysis. This allows
for the detection of persistent or recurrent recipient
hematopoiesis, which can be used as a surrogate marker
for disease relapse. Also, decreasing donor chimerism can
be the first sign of graft failure.
Chimerism analysis can be performed on unfractio-
nated peripheral blood cells, bone marrow or isolated
cell lineages. A patient can either have a complete chi-
merism (CC), when the % of donor origin cells exceeds
the upper detection limit of the analysis used (usually
corresponding with donor chimerism of >95-99.9%
depending on the sensitivity of the used test cfr. infra),
or a mixed chimerism (MC) where donor and recipient
hematopoietic cells coexist. However, the state of
a patient’s chimerism is subject to change over time
and a patient can present with an increasing or decreas-
ing donor chimerism, i.e. an increasing or decreasing
amount of donor hematopoiesis compared to previous
analysis. Lastly, levels of chimerism are not necessarily
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the same between different cell populations and
patients can present with a split chimerism, where CC
has been achieved in one or more cell lineages but MC
still exists in other cell lineages [1–5]. (Table 1)
Analysis of a patient’s chimerism status is based on the
identification of the genetic profile of the patient and his
or her donor in the recipient’s blood or bonemarrow. This
is accomplished by the analysis of differences in poly-
morphic genetic markers such as short tandem repeats
(STR), single nucleotide polymorphisms (SNP) or inser-
tions and deletions between donor and recipient
[1,2,4,7,8]. Both recipient and donor pre-transplant DNA
samples need to be available for genotyping to establish
pre-transplant genetic profiles [2]. Ideally, whole blood
samples should be provided, but cheek swabs can be
used as an alternative if peripheral blood counts are
too low.
Short tandem repeats are units of 2 to 6 base pairs
in length repeated multiple times within a given DNA
fragment. These DNA fragments have a highly poly-
morphic nature between individuals, with a variable
number of repeats at each tested locus. By using PCR-
based amplification of these loci, patient and donor
DNA can be identified based on the length of the
resulting PCR products [2,9–12]. There are several com-
mercial kits available with up to 16 STR markers, ori-
ginally designed for use in forensic identification,
which cover multiple ethnic backgrounds [2,9,12].
Short tandem repeat based chimerism analysis has
a reported sensitivity of 1-5% [1,10,11,13] with a high
reproducibility and an applicability (or informativity,
i.e. the number of donor/recipient couples that can
be evaluated using this technique) of nearly 100%
[14]. (Table 2)
Since the early 2000’s real time quantitative PCR (rt-
qPCR) analysis of SNPs or insertions and deletions is also
possible [1,2,4,7,8]. These analyses are based on real time
amplification of known SNPs or insertion/deletion poly-
morphisms, for which several commercial kits are avail-
able [1,9,10,14,15]. This technique has a reported
sensitivity of 0.01–0.1% [14–16] and a high degree of
informativity of >90% [9,14]. (Table 2) Various studies
have shown a high concordance rate between STR-
based methods and qPCR, the described discordant
results have all been in line with the reported differences
in sensitivity between both analyses (with rt-qPCR detect-
ing MC earlier than STR-based techniques) [9,10,16–19].
Novel techniques using digital droplet PCRmethods
are in development but as of yet, have not been stan-
dardized for use outside clinical trials, as no standard
testing panel exists [4,20].
In sex mismatched HSCT X/Y FISH can be used for
chimerism detection. This technique is well standardized,
has shown a high sensitivity of 0,1–0,001% and can be
rapidly performed in most laboratories. However, as it is
restricted to sex mismatched HSCTs it has a lower clinical
applicability (approximately 50% of patients receive a sex
mismatched HSCT) [1,21]. (Table 2)
Semi quantitative fluorescent PCR of STRs
remains the current gold standard for chimerism
monitoring because of the high level of standardi-
zation, high applicability, reproducibility, cost-
effectiveness, short laboratory turnaround time and
clinical validation in multiple follow-up studies
[4,9,22,23]. Currently, it remains the most commonly
used method for chimerism analysis in Belgium. In
a survey carried out amongst 12 Belgian allotrans-
plant centers, this technique was used in 11 out of
the 12 centers routinely using chimerism analysis in
post-HSCT follow-up.




X/Y FISH 0,001–0,1% ±50% – only applicable in sex
mismatched HSCT
STR-PCR 1-5% (nearly) 100%
Rt-qPCR 0,01–0,1% >90%
*The informativity or applicability of the test refers to the proportion of
donor/recipient couples that can be evaluated using this technique.
Table 1. Definitions of chimerism and engraftment.
Chimerism state Definition Comment
Complete chimerism (CC) All hematopoietic cells are of donor origin [1] Usually defined as >95-99.9% donor origin of hematopoietic cells
depending on test sensitivity (% > detection limit for chosen
analysis)
Mixed chimerism (MC) Presence of both donor and recipient
hematopoietic cells [1]
Split chimerism CC has been achieved in one or more cell lineage
but MC still exists in other cell lineages [1]
Engraftment First of 3 consecutive days with absolute
neutrophil count (ANC) >500/µL (of donor
origin) [6]
Platelet engraftment: sustained platelet count >20.000/µL for 7 days
without transfusion [6]
Primary graft failure Absence of engraftment/hematological recovery
with donor cells in the first month post-HSCT [6]
ANC<500/µL d + 28 [6]
In case of RIC or NMA HSCT autologous recovery of ANC is possible,
confirmation of graft failure by chimerism analysis is required [6]
Secondary graft failure Loss of graft function (ANC < 500/µL) after initial
engraftment [6]
Donor chimerism >5%
Without secondary cause such as relapse, infection, marrow
toxicity. . .[6]
Autologous recovery 100% recipient origin of hematopoietic cells [1]
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Clinical application of chimerism analysis
Monitoring the dynamics or kinetics of a patient’s chimer-
ism status by serial analysis at fixed time points, as well as
on suspicion of relapse or graft failure, can be used to
monitor engraftment levels, aswell as disease control and
possible relapse [9,24–26]. Chimerism kinetics post-HSCT
varies greatly amongst patients and is influenced,
amongst other factors, by the conditioning regimen
[24,27–31].
The use of RIC and Non myeloablative (NMA) con-
ditioning regimens has allowed older patients and
patients with existing co-morbidities to proceed to
allogeneic HSCT by reducing the treatment-related
morbidity and mortality. These regimens do not rely
on an immediate complete eradication of host hema-
topoiesis, but rather on the immunologic graft versus
tumor (GVT) effect, allowing for a faster hematological
recovery post-HSCT. However, MC is observed at the
time of engraftment in nearly all patients who undergo
NMA conditioning and a substantial subset of patients
undergoing RIC transplantation [24,30]. In contrast,
patients who receive a Myeloablative conditioning
(MAC) regimen tend to reach CC at an earlier time
point post-HSCT, with the majority of patients reaching
CC at day 30, especially when using a TBI-based regi-
men [5,29,32,33].
Secondary graft failure
The presence of MC (in both whole blood, bone marrow
or T-cells) has been linked to the occurrence of second-
ary graft failure in both malignant and non-malignant
disease, with a proportional increase of the risk of sec-
ondary graft failure with an increasing degree of MC
[24,29,34,35]. Both Lee et al. [29] and Lucarelli et al. [34]
showed that secondary graft failure mostly occurred in
those patients with a MC of <75% hematopoietic cells of
donor origin. Baron et al. [24] showed that the presence
of <50% donor-derived T-cells or NK-cells on day 14 after
non myeloablative (NMA) transplant, was associated
with a higher risk of graft rejection.
In a cohort of 335 patients transplanted for thalasse-
mia after MAC, published by Lucarelli et al. [34], no
secondary graft failure was seen in patients achieving
CC at 2 months post-HSCT, whereas 35 out of the 108
patients with MC at 2 months post-HSCT did develop
graft failure. The risk of secondary graft failure was
correlated with the degree of chimerism at day 60.
Ninety percent of the patients with a MC <75% donor
origin on peripheral blood went on to reject their graft
versus only 13% of patients who had a donor chimer-
ism of >90% on peripheral blood [34,36].
In a cohort of 91 patients, who received HSCT for
severe aplastic anemia (SAA), no secondary graft failure
was observed in patients who achieved CC immediately
after HSCT (at day 30) or who showed an increasing
donor chimerism post-HSCT andwho achieved CCwithin
1 year post transplant. However, a decrease in donor
chimerism of ≥15% on peripheral blood during follow-
up was a significant risk factor for secondary graft failure,
with 10/14 patients (71%) going on to experience sec-
ondary graft failure during further follow-up (median
time to graft failure not reported). In the majority of
patients, this decreasing donor chimerism of ≥15% and
subsequent graft failure (7/10) occurred during the taper-
ing of immunosuppressive therapy [35].
In a smaller patient cohort, consisting of 34 children
transplanted for SAA inGermany, 4/34 patients presented
with a donor chimerismof <70%during follow-up. Twoof
these patients went on to experience secondary graft
failure requiring a second HSCT. In light of these results
the remaining 2 patients received DLI infusion to prevent
graft failure [37].
Chimerism analysis and risk of relapse in
malignant disease
Relapse prediction using chimerism relies on the inter-
pretation of chimerism kinetics. A sustained MC or
decreasing donor chimerism early after HSCT has been
shown to be an independent risk factor for relapse and
impaired survival after MAC, RIC or NMA conditioning, in
both adults and children, independent of the under-
lying hematological malignancy [9,25–27,31,32,38–40].
The largest described adult cohort to date, which
consisted of 688 retrospectively analysed patients who
received T-cell replete RIC transplants for hematologi-
cal malignancies, showed that peripheral blood donor
chimerism of <90% at day 30 and day 100 was inde-
pendently associated with higher relapse rate and
lower Progression free survival (PFS). A donor chimer-
ism <90% at day 100 was also independently asso-
ciated with impaired Overall survival (OS). Day 100
chimerism was the best predictor of outcome [25].
The time needed to reach CC was also shown to be
associated with the probability of relapse [32,38,41].
Chen et al. [38] showed that early achievement of
complete chimerism in pediatric ALL patients after
MAC transplant (median 15 days) was associated with
a longer PFS. Similarly, Lassaletta et al. [41] showed
that the probability of relapse in patients with hema-
tological malignancies was significantly lower in
patients who reached a CC by day 30.
In patients with a disease characterized by a specific
measurable residual disease (MRD) marker, early detec-
tion of relapse is primarily based on MRD detection by
molecular biology or immunophenotype. However, as
these disease markers can be lost on the occasion of
disease relapse, a decreasing donor chimerism can be
the first sign of disease relapse. It is also important to
remember that up to 50% of the transplant population
does not have a specific MRDmarker that can be used in
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follow up [9,42]. The use of repetitive chimerism analy-
sis, therefore, remains a necessary part of post-
transplant follow-up, especially in the case of RIC or
NMA transplants [1,9].
Additionally, chimerism analysis can be used to con-
firm the presence of donor cell-derived leukemia. In this
case, leukemia relapse occurs post-HSCT without
decrease in donor chimerism, i.e. in patients with CC
[43,44]. The use of FISH or cytogenetics for chimerism
analysis in sex mismatched HSCT in this indication is
limited, as loss of sex chromosomes with age as well as
in hematological malignancies has been clearly
described [44–46].
There is no general consensus on the ideal regimen
of post-HSCT chimerism follow-up. Intervals ranging
from weekly to monthly chimerism analysis have
been used in clinical trials. We want to stress that it is
primarily the dynamics or kinetics of a patient’s chimer-
ism status, which can only be determined by serial
analysis at regular intervals, that will allow for the
interpretation of the risk of (impending) relapse or
secondary graft failure [9,24–26].
Based on the trials available and taking into account
the practicality of these regimens in a ‘real world’ set-
ting, we would propose that chimerism analysis on
unfractionated peripheral blood and T-cells should ide-
ally be performed at 1, 3, 6 and 12 months post trans-
plant in case of MAC transplantation and at 1, 2, 3, 6 and
12 months post-HSCT in case of RIC or NMA transplant,
in order to adequately interpret the underlying kinetics.
In case of CC in MAC transplants follow-up can be
limited. Further analysis is recommended at least once
a year up to a minimum of 5 years post-HSCT tomonitor
for secondary graft failure and as a marker of possible
minimal residual disease and relapse. In patients with-
out a MRD marker chimerism analysis should be
considered as part of routine disease surveillance in
follow-up [24–26,28,29,31,32,35–38,41].
As the time frame between changes in donor chi-
merism and occurrence of relapse is unpredictable
(ranging from 1 to several weeks [32]), serial analyses
should be performed at short time intervals when
a decreasing donor chimerism or persistent MC is
detected. Taking into account the required turnaround
time of results as well as the short time interval
observed between occurrence of a decreasing donor
chimerism and occurrence of relapse, chimerism ana-
lysis performed every 2 weeks on peripheral blood
samples are considered feasible. Laboratory turn-
around time of samples should therefore be reduced
to a minimum in these circumstances and ideally be
limited to a maximum of 5 days [2].
Chimerism analysis in non-malignant disease
Contrary to malignant hematological diseases, complete
donor chimerism is not a prerequisite for cure in patients
with non-malignant hematological diseases, such as
hemoglobinopathies, primary immunodeficiencies and
bone marrow failure syndromes, where a partial replace-
ment of autologous hematopoiesis can result in adequate
clinical outcomes. Achieving a state of stable MC can be
sufficient to improve hematopoiesis, restore immuno-
competence or replace the deficient enzyme in these
patients [1,4,47,48].
In order to reduce transplant-related morbidity
and mortality, the use of RIC regimens is more com-
mon than in malignant disease. However, this results
in a higher likelihood of MC post-HSCT and an
increased risk of graft rejection and non-
engraftment [1,34,35,49].
Long-term stable MC without disease relapse or
graft rejection has been described in a considerable
number of patients after HSCT for nonmalignant dis-
ease and has been described as late as 13 years post-
HSCT in published series. In our personal experience,
we have identified patients with lifelong stable MC
after HSCT for immunodeficiency syndromes [34,50].
Long-term follow-up studies have shown that fluctua-
tions in chimerism level are mostly seen during the first
24 months post-HSCT, with more stable patterns emer-
ging in later follow up [48,50]. A matched case-control
analysis between patients transplanted for nonmalig-
nant disease with a long-term stable MC and patients
with CC post-HSCT performed by Stikvoort et al. [48,50]
at a median time of 10 years post-HSCT, showed that
there was no difference in prognosis between both
patient groups. Interestingly, in a study of 85 children
who underwent HSCT for nonmalignant disease, Faraci
et al. [51] found that OS at 3 years was higher in
patients with stable MC compared to patients with CC.
The presence of a MC in itself is therefore not
equivalent to disease relapse or impending secondary
graft failure in patients transplanted for non-malignant
disease. Identification of a stable mixed chimerism is
an important feature of clinical follow-up requiring
continuation of chimerism analysis for longer periods
of time.
Pre-emptive post-HSCT interventions based on
chimerism analysis
The reduction of immune suppression and use of
donor lymphocyte infusions (DLI) can be used to con-
vert a MC to CC, thereby boosting the GVT effect [52–
56]. Achievement of CC as result of these interventions
has been shown to provide a survival benefit [54,55].
In a prospective study of 81 pediatric patients
undergoing HSCT for AML and ALL, DLI were adminis-
tered post-HSCT if MC (defined as <99% cells of donor
origin on peripheral blood using rt-qPCR) was present
on 2 consecutive weekly analyses. Thirty-eight patients
received DLIs, with 33 of these patients showing an
increase in donor chimerism and 3 patients converting
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to CC. More importantly, an increase in OS at 3 years
was observed in patients achieving CC compared to
those with partial or no response [54]. Additionally,
a prospective study which included 71 pediatric
patients transplanted for AML found that the rapid
tapering of immune suppression and subsequent
administration of DLIs in patients presenting with MC
on 2 consecutive peripheral blood or bone marrow
samples until achievement of CC could improve
RFS [55].
Donor lymphocyte infusion has also been shown to
improve chimerism in non-malignant diseases. In
a retrospective analysis of 26 pediatric patients receiv-
ing DLI for MC post-HSCT for non-malignant disease,
56% of patients showed an improvement of their chi-
merism status, with conversion to CC in 37% [56].
Cell source
Lineage-specific chimerism analysis on peripheral
blood samples
Chimerism analysis of specific white blood cell subsets
can provide a higher sensitivity and specificity for the
detection of recipient hematopoiesis allowing for an
earlier and more accurate detection of possible relapse
[8,57,58]. Cell populations as small as 1% of the total
white blood cell count can be isolated from blood
samples and used for chimerism analysis [2,8,57–59].
CD34+ chimerism
CD34 is expressed on the majority of blast cells in AML,
MDS and ALL populations and can be used in in these
patient populations as a more sensitive predictor of
disease relapse compared to whole blood chimerism,
especially in the absence of a disease-specific MRD
marker [57–61]. Unnikrishnan et al. [60] were able to
show that a CD34+ donor chimerism of <80% could
predict relapse with a sensitivity of 100% and specifi-
city of 67%, compared to 14% and 83% for donor
chimerism on whole blood (based on a population of
13 patients, 7 of which relapsed post-HSCT). Similarly,
Hoffman et al. [61] showed that a CD34+ donor chi-
merism of <80% had a 100% sensitivity for prediction
of relapse. In a study carried out in 35 relapsed post-
HSCT patients treated with MAC or RIC by Bornhauser
et al. [59], a CD34+ donor chimerism of <80% had
a positive predictive value for relapse of 80% and was
significantly associated with a decreased OS and PFS at
4 years.
Based on the available evidence, a decline in CD34
+ donor chimerism occurs earlier prior to relapse com-
pared to a decline in peripheral whole blood chimer-
ism [58–61]. In the patients studied by Urrikrishnan
et al. [60] who showed hematological relapse,
a decline of CD34+ donor chimerism could be docu-
mented at a median of 69 days prior to documentation
of relapse (with a range of 4–175 days) and in the
population studied by Thiede et al. [58] a decline in
CD34+ donor chimerism could be detected 12–97 days
prior to clinical relapse in 20/22 patients.
CD3 chimerism
The presence of mixed T-cell chimerism has been
linked to an increased relapse risk, inferior PFS and
a higher graft rejection rate [25,31,33,62,63]. The use
of T-cell donor chimerism, in addition to whole blood
analysis, can provide a higher sensitivity for the detec-
tion of MC, as significant discrepancies between per-
ipheral blood chimerism and CD3+ chimerism have
been observed in about 10% of the HSCT population
[32,64], most often occurring in MAC transplants [32].
In these patients, the presence of a MC can be missed if
analysis is only performed on whole blood samples
[32,64].
In the cohort of 688 patients retrospectively ana-
lysed by Koreth et al. [25], a donor T-cell chimerism of
<70% at day 100 was associated with a higher relapse
rate and an impaired PFS in multivariate analysis.
However, use of T-cell chimerism did not provide
a higher predictive capacity for PFS than day 100
whole blood chimerism in multivariate analysis.
Lee et al. [65] showed that patients transplanted for
AML and MDS with a mixed T-cell chimerism of ≤85%
between day 90 and 120 had a significantly lower PFS
at 3 years post-transplant compared to patients with
a T-cell donor chimerism of >85%. A comparison with
whole blood chimerism, however, was not made. Also,
in a retrospective analysis of 322 HSCT patients treated
for hematological malignancies with a non-
myeloablative conditioning, performed by Baron
et al. [62], the achievement of full donor T-cell chimer-
ism (≥95%) was correlated with a significantly
decreased risk of disease progression or disease
relapse compared to patients with <95% donor T-cell
chimerism. Unfortunately, no data was presented on
whole blood chimerism in these patients.
We would suggest using a combination of T-cell
chimerism and whole blood chimerism in routine fol-
low-up at day 30, 60 and 90 in case of RIC transplant, in
order to correctly interpret chimerism kinetics.
Minimally it should be obtained at day 90–100 post-
HSCT and in cases presenting with a persistent MC or
decreasing donor chimerism. In case of discrepancies
between whole blood chimerism and T-cell chimerism,
a combination of both tests should be used in further
follow-up. A decreasing T-cell chimerism, in spite of
stable whole blood chimerism, should prompt clinical
action and decision-making.
Other cell lineages
Although other cell lineages such as CD19 + B cells and
NK-cells have been used in clinical trials, there is
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currently not enough evidence to standardize their use
in routine clinical follow-up [4,57].
Bone marrow chimerism
In addition to chimerism analysis on peripheral blood,
bone marrow analysis can also be performed. The
additional value of bone marrow chimerism in stan-
dard follow-up is not well established due to a lack of
follow-up studies analyzing the role of bone marrow
chimerism in relation to relapse or graft failure. It has
been shown that the use of bone marrow for chimer-
ism analysis in combination with peripheral blood
analysis can increase the sensitivity of MC detection.
However, it also results in a larger number of patients
identified with MC who present with normal engraft-
ment kinetics and who do not relapse post-HSCT
[9,18]. This could be due to a contamination of bone
marrow samples by autologous stromal cells [9,18] and
should be taken into account when interpreting results
of bone marrow chimerism. Additionally, results of
chimerism analysis in peripheral blood have been
shown to be equivalent to results from analysis of
bone marrow [66]. A study performed by Rauwerdink
et al. [66] could show no difference in results between
chimerism analysis performed on unfractionated per-
ipheral blood and bone marrow in 42 patients at day
30, 60 and 90 post-HSCT.
Clinical use of chimerism analysis:
recommendations
(1) After MAC, chimerism analysis on unfractio-
nated peripheral blood is ideally performed at
1, 3, 6 and 12 months post-transplant. T-cell
chimerism should ideally be performed at
3 months post-transplant. Analyses can be lim-
ited if CC has been reached. Further analysis is
recommended at least once a year and should
be considered as part of routine disease surveil-
lance in patients without MRD marker.
(2) In case of RIC or NMA conditioning regimens,
a sequential follow up with monitoring of chi-
merism kinetics is essential. Chimerism analysis
on unfractionated peripheral blood should be
performed at 1, 2, 3, 6 and 12 months post-
HSCT. Mixed chimerism with <90% cells at day
30 and day 100 can be used to identify patients
at high risk of relapse and impaired survival.
Ideally, T-cell chimerism analysis should be
obtained at 1, 2, 3 and 6 months post-HSCT or
at the least at 3 months post-transplant and in
the case of persistent MC or decreasing donor
chimerism. Mixed T-cell chimerism <85-90% can
be used to identify patients at high risk of dis-
ease relapse and impaired survival. Further, fol-
low up of chimerism analysis is recommended at
least once a year for a minimum of 5 years post-
HSCT and should be considered as part of rou-
tine disease surveillance in patients without
MRD marker. More frequent analysis is indicated
when graft loss or rejection is suspected clini-
cally, or in the event of a decreasing donor
chimerism, at intervals of 2 weeks to 1 month.
(3) If available, MRD markers should be used for
monitoring of relapse. Chimerism can be used
to monitor disease relapse when no specific
MRD markers are available. Combination of chi-
merism and follow-up of known MRD markers
may provide additional information in the case
of loss of a specific MRD marker on relapse.
(4) CD34+ chimerism on sorted peripheral blood
cells, when available, can be used as an alter-
native to specific MRD markers in AML, MDS and
ALL if leukemic blasts are known to express
CD34.
(5) Bone marrow chimerism analysis can be used in
addition to or instead of peripheral whole blood
and lineage-specific chimerism analysis.
Chimerism analysis on bone marrow can be
considered when bone marrow aspirate is per-
formed in routine clinical follow-up.
(6) Following therapeutic intervention sequential
follow up of chimerism on unfractionated per-
ipheral blood every 2–4 weeks is indicated.
Addition of T-cell chimerism can be considered
as useful. If stable CC is reached, analyses can be
performed every 3–6 months.
(7) Following HSCT for non-malignant disorders
(other than aplastic anemia) chimerism analysis
should be performed at 1, 2 and 3 months post-
HSCT. If CC has been reached further follow-up
is indicated when there is a clinical suspicion of
rejection or relapse. In case of persistent MC,
further follow-up at 2–3 monthly intervals is
indicated until 24 months post-HSCT. In patients
transplanted for aplastic anemia longer follow-
up of chimerism is recommended, including
during tapering of immune suppression.
Current practice in Belgium
There is at present no routine or standard practice
used in Belgium when it comes to monitoring chimer-
ism post-HSCT. A survey undertaken amongst 12 out of
the 13 transplant centres in Belgium in 2019 showed
that routine chimerism analysis was part of standard
patient follow-up after allogeneic transplantation in
11/12 centres.
All centres performing chimerism analysis use
whole blood chimerism analysis as part of their routine
follow-up. In 6/11 centres whole blood, bone marrow
and CD3 chimerism are routinely performed, whereas
in 4/11 centres whole blood and whole bone marrow
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are used (with CD3 chimerism available on indication)
and in 1/11 centres only whole blood is used for rou-
tine follow-up. CD34+ bone marrow chimerism analy-
sis has been used in several centres but only in specific
cases and never in routine follow-up. Although CD34
+ chimerism analysis on peripheral blood samples has
been frequently used in clinical trials it is not currently
performed in Belgium [59–61].
Current reimbursement criteria in Belgium allow for
a maximum of six chimerism analyses on either whole
blood, bone marrow or T-cells in the first year after
transplant and a maximum of four analyses per year in
the subsequent 4 years. This allows for only a minimal
follow up of chimerism at the present time, without
allowing for the eventuality of follow-up of split chimer-
ism nor for follow-up of chimerism after a possible post-
HSCT intervention.
Conclusion
Serial chimerism analyses are an indispensible part of
post-allogeneic HSCT follow-up, as there is clear evi-
dence that the degree of chimerism and especially the
observed chimerism kinetics are closely related to the
risk of disease relapse and graft rejection. Close post-
HSCT follow-up of chimerism by repeated analyses will
allow for the identification of patients with an indica-
tion for post-HSCT therapeutic interventions and their
early application. The suggested frequency of follow-
up of a patient’s degree of chimerism, both in the
immediate post-transplant setting and following any
post-transplant therapeutic intervention is therefore of
paramount importance to provide optimal-
personalized medicine, aiming at an increased survival
post-allogeneic HSCT. Unfortunately, current reimbur-
sement criteria do not allow for optimal patient follow-
up. We would therefore urge the Health Authorities to
revise these criteria in the light of these new guide-
lines, in order to provide adequate patient care.
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